NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.
Follow NVCR
NovoCure Limited (NVCR) Piotroski F-score
NovoCure Limited's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (1.00) |
| FY2024 | 5 | 4.00 |
| FY2023 | 1 | (3.00) |
| FY2022 | 4 | 0.00 |
| FY2021 | 4 | (2.00) |
| FY2020 | 6 | (1.00) |
| FY2019 | 7 | 3.00 |
| FY2018 | 4 | 0.00 |
| FY2017 | 4 | 0.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (13.32%) | (14.13%) | Fail | 0 |
| Positive operating cash flow | (49.03m) | (26.37m) | Fail | 0 |
| Rising return on assets | (13.32%) | (14.13%) | Pass | 1 |
| Cash flow above net income | 87.20m | 142.26m | Pass | 1 |
| Falling long-term leverage | 0.23 | 0.10 | Fail | 0 |
| Rising current ratio | 2.90 | 1.46 | Pass | 1 |
| No new shares issued | 111,472,000 | 107,834,000 | Fail | 0 |
| Rising gross margin | 74.54% | 77.33% | Fail | 0 |
| Rising asset turnover | 0.64 | 0.51 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BVS Bioventus Inc. compare | 8 |
| ATEC Alphatec Holdings, Inc. compare | 6 |
| INSP Inspire Medical Systems, Inc. compare | 6 |
| AXGN AxoGen, Inc. compare | 5 |
| UFPT UFP Technologies, Inc. compare | 5 |
| CNMD CONMED Corporation compare | 5 |
| ESTA Establishment Labs Holdings Inc. compare | 5 |
| NVCR NovoCure Limited | 4 |
| BFLY Butterfly Network, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover